OMER vs. PCRX, NKTR, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, and BMY
Should you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), and Bristol-Myers Squibb (BMY). These companies are all part of the "pharmaceuticals" industry.
Omeros vs.
Omeros (NASDAQ:OMER) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
48.8% of Omeros shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 12.3% of Omeros shares are owned by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Pacira BioSciences has higher revenue and earnings than Omeros. Pacira BioSciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.
Omeros has a net margin of 0.00% compared to Pacira BioSciences' net margin of -13.07%. Pacira BioSciences' return on equity of 13.42% beat Omeros' return on equity.
Omeros currently has a consensus target price of $22.50, suggesting a potential upside of 141.16%. Pacira BioSciences has a consensus target price of $24.50, suggesting a potential upside of 9.57%. Given Omeros' stronger consensus rating and higher probable upside, research analysts clearly believe Omeros is more favorable than Pacira BioSciences.
Pacira BioSciences received 80 more outperform votes than Omeros when rated by MarketBeat users. Likewise, 71.55% of users gave Pacira BioSciences an outperform vote while only 71.02% of users gave Omeros an outperform vote.
Omeros has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.
In the previous week, Pacira BioSciences had 28 more articles in the media than Omeros. MarketBeat recorded 40 mentions for Pacira BioSciences and 12 mentions for Omeros. Omeros' average media sentiment score of 0.48 beat Pacira BioSciences' score of 0.17 indicating that Omeros is being referred to more favorably in the media.
Summary
Pacira BioSciences beats Omeros on 10 of the 18 factors compared between the two stocks.
Get Omeros News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:OMER) was last updated on 1/20/2025 by MarketBeat.com Staff
